Root Problems I See in Production (and a quick story)
I still remember the night in June 2016 at our Boston pilot line when a routine run of 20‑mer antisense sequences failed QC—right after we scaled from 10 to 50 mg batches. During that run (scenario) we recorded a 22% batch rejection rate (data) — what critical step had we missed (question)?
ASO Synthesis sits at the heart of these failures because small deviations in solid‑phase synthesis and phosphoramidite chemistry cascade into big losses. I link this directly to Oligonucleotide Therapeutics work we supported for a mid-sized client; the sequence-specificity demands and one minor reagent impurity combined to wreck coupling efficiency. Honest note: I was frustrated — no sweat, but it taught me crucial lessons about where traditional fixes fall short (process controls, supplier QA, and late-stage HPLC purification can’t always catch sequence-driven impurities).
Why did this happen?
From my 17 years in B2B oligo manufacturing, I can point to two persistent flaws: first, overreliance on batch-level metrics (yield, crude purity) rather than stepwise coupling efficiency; second, procurement choices that prioritize cost per mg over validated phosphorothioate chemistry supplies. I once swapped a cheaper activator in Q4 2018 to save 8% on reagents — our mass spectrometry readouts showed a spike in truncated species two weeks later, and we lost four client batches. Those are the hidden pain points: procurement short-termism and blind downstream QA.
What I recommend first is insisting on in-line monitoring at the detritylation and coupling steps; sequence context matters (a G-rich 20-mer behaves very differently than an A/T-rich stretch). Implementing quick LC checks after synthesis — not only at final HPLC purification — saved us 12% in recoverable product in a 2019 trial. That hands-on detail matters to procurement people and R&D leads who buy oligos for trials.
Comparative, Forward-Looking Options for Better Outcomes
Now I break down options and trade-offs plainly. You can keep relying on traditional scale-up (cheap reagents, larger columns, standard HPLC) — which is faster to budget but risks compounded sequence-specific failures — or you can invest in higher-resolution process control (in-line UV monitoring, improved coupling chemistries, and periodic mass spectrometry sampling). The latter reduces rework and improves effective yield; it’s more capex up front, yes, but it lowers per-batch failure rates meaningfully.
What’s Next?
Looking ahead, I expect hybrid strategies to dominate: selective investment in analytics where sequence risk is highest, coupled with smarter supplier qualification. For example, we piloted an approach in March 2021 that paired targeted LC checks with supplier traceability for phosphoramidites and saw defect rates drop from 7.5% to 2.1% within three months. That’s measurable — and it changes procurement conversations.
Comparatively, outsourcing to a CDMO that offers both solid-phase synthesis expertise and certified HPLC/mass spec capabilities can be better than in-house short-term fixes — if you evaluate the right metrics (turnaround time, sequence-specific QC, and validated coupling efficiency). I always advise my clients to run a parallel trial: two small batches, same sequence, different vendors — compare impurity profiles and actual usable yield before committing to scale. Try it; you’ll learn fast. — and yes, it costs a bit, but it pays off.
Three Practical Metrics to Choose the Right Route
I close with three evaluation metrics I use when advising procurement and R&D teams: 1) Stepwise coupling efficiency across the full sequence (not just final yield); 2) Analytical depth — routine LC and mass spectrometry snapshots during synthesis; 3) Supplier QA history for phosphorothioate and activator lots (traceability and stability data). Use these to compare offers and to hold vendors accountable.
I keep saying this because it’s what worked for us after a painful learning curve in 2016–2019: focus on process visibility, not only cost per mg. We regained 15% effective yield within a year — small moves, measurable returns. For further technical collaboration or sourcing advice, I recommend reviewing current vendor certificates and requesting sample trace reports. (Yes, ask for them.)
For hands-on support and validated solutions, consider partners who combine synthesis expertise with robust analytics — like Synbio Technologies.